WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today presentations at the upcoming Alzheimer’s Association International Conference (AAIC) being held in Vancouver, British Columbia, Canada on July 14-19, 2012. At the conference, Merck scientists are scheduled to present results from multiple preclinical and clinical studies investigating the safety and efficacy of ß-amyloid precursor protein site cleaving enzyme (BACE) inhibitors, including MK-8931, the company’s lead compound currently being investigated as a potential treatment for Alzheimer’s disease.
